RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.

EHA Library, Ciro Rinaldi, 385453

LONG-TERM OUTCOMES OF STEM CELL TRANSPLANT IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH VENETOCLAX + HMA THERAPIES

EHA Library, Keith Pratz, 386354

SAFETY AND EFFICACY UPDATE FROM CLI120-001: A PHASE1B DOSE ESCALATION STUDY IN RELAPSE-REFRACTORY ACUTE MYELOID LEUKEMIA AND HIGH-RISK MYELODYSPLASIA

EHA Library, Ewa Lech-Marańda, 386355

DISTINCTIVE CLONAL EVOLUTION PATTERN AND PROGNOSTIC SIGNIFICANCE OF THE CLONALITY OF KRAS MUTATIONS IN KMT2A-REARRANGED ACUTE MYELOID LEUKEMIA

EHA Library, Hidemasa Matsuo, 386356

CAN MULTIPARAMETRIC FLOW CYTOMETRY OF PERIPHERAL BLOOD CHALLENGE BONE MARROW ANALYSES FOR DETECTION OF MEASURABLE RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA?

EHA Library, Jonas Schadt, 386357

THE EFFECT OF AGE AND TREATMENT ON THE PREDICTIVE VALUE OF MEASURABLE RESIDUAL DISEASE: IMPLICATIONS FOR THE CLINICAL MANAGEMENT OF ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Francesco Mannelli, 386358

CPX-351 INDUCTION IS ABLE TO INDUCE MRD NEGATIVE CR IN A SIGNIFICATIVE PROPORTION OF VERY HIGH RISK AML PATIENTS, REGARDLESS OF MUTATIONAL BURDEN, ALLOWING FOR BRIDGING TO TRANSPLANTATION

EHA Library, Carola Riva, 386359

MIDOSTAURIN PLUS 7+3 OR QUIZARTINIB PLUS 7+3 IN FLT3-ITD MUTATED AML

EHA Library, Adolfo De La Fuente, 386360

KINETICS AND PROGNOSTIC VALUE OF MEASURABLE RESIDUAL DISEASE (MRD) IN PATIENTS DIAGNOSED WITH ACUTE MYELOID LEUKEMIA (AML) TREATED WITH VENETOCLAX IN COMBINATION WITH HYPOMETHYLATING AGENTS.

EHA Library, Carlos Jimenez-Vicente, 386361

A FULLY AUTOMATED SUPERVISED AI-BASED CELL CLASSIFIER TO ACCURATELY FLAG PATHOLOGICAL SIGNATURE CELLS IN 28,285 REAL-WORLD BLOOD SMEARS

EHA Library, Christopher Maier, 386362

FIRST-IN-HUMAN TRIAL OF TOCILIZUMAB IN COMBINATION WITH A STANDARD INDUCTION CHEMOTHERAPY IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS: THE PHASE 1 TOCILAM STUDY.

EHA Library, Pierre Peterlin, 386363

OUTCOMES OF INVESTIGATIONAL AGENTS VS STANDARD THERAPIES IN AML AT SALVAGE 2 AND BEYOND

EHA Library, Daniel Nguyen, 386364

A FIRST-IN-HUMAN PHASE 1 STUDY OF IO-202 (ANTI-LILRB4 MAB) IN ACUTE MYELOID LEUKEMIA (AML) WITH MONOCYTIC DIFFERENTIATION AND CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) PATIENTS

EHA Library, Courtney DiNardo, 386365

SAFETY AND TOLERABILITY OF AZD0466 AS MONOTHERAPY FOR PATIENTS WITH ADVANCED HEMATOLOGICAL MALIGNANCIES - PRELIMINARY RESULTS FROM AN ONGOING PHASE I/II TRIAL

EHA Library, Giovanni Marconi, 386366

FAST-TRACK MEASURABLE RESIDUAL DISEASE DETECTION BY MULTIPARAMETRIC FLOW CYTOMETRY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION

EHA Library, Maximilian Roehnert, 386367

A PHASE 1 STUDY OF HMPL-306, A DUAL INHIBITOR OF MUTANT ISOCITRATE DEHYDROGENASE (IDH) 1 AND 2, IN PTS WITH RELAPSED/REFRACTORY MYELOID HEMATOLOGICAL MALIGNANCIES HARBORING IDH1 AND/OR 2 MUTATIONS

EHA Library, Lijuan Hu, 386368

RESULTS FROM A PHASE 1 CLINICAL STUDY OF THE ALL-ORAL REGIMEN OF CC-486 AND VENETOCLAX FOR RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Maria Amaya, 386369

REAL-WORLD USE OF VENETOCLAX (VEN) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) IN A US REAL-WORLD EVIDENCE DATABASE (COTA)

EHA Library, Amer M. Zeidan, 386370

A PHASE I/II STUDY TO ASSESS SAFETY, TOLERABILITY AND PRELIMINARY EFFICACY OF BEXMARILIMAB IN COMBINATION WITH STANDARD OF CARE IN PATIENTS WITH MYELOID MALIGNANCIES (BEXMAB)

EHA Library, Mika Kontro, 386371

CONSECUTIVE DAY DOSING OF HIGH-DOSE CYTARABINE CONSOLIDATION OVER 3 DAYS IS FEASIBLE IN OLDER PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Rithin Nedumannil, 386372

SINGLE-SYSTEM UNIFOCAL ADULT LANGERHANS CELL HISTIOCYTOSIS: A SINGLE-CENTER RETROSPECTIVE STUDY

EHA Library, Xin-xin Cao, 386373

VENETOCLAX (VEN) COMBINED WITH FLAG-IDA IS AN EFFECTIVE REGIMEN FOR PATIENTS (PTS) WITH NEWLY DIAGNOSED (ND) AND RELAPSED/REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)

EHA Library, Madelyn Burkart, 386374

MACHINE LEARNING AND RESPONSE TO INDUCTION CHEMOTHERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Heba Elhaddad, 386375

UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING

EHA Library, Jacopo Nanni, 386376

PRELIMINARY RESULTS OF A PHASE 1, FIRST-IN-HUMAN STUDY OF INA03, AN ANTI-CD71 ANTIBODY-DRUG CONJUGATE IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) ACUTE LEUKEMIAS

EHA Library, Sylvain Garciaz, 386377

EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.

EHA Library, GIAN LUCA MORELLI, 386378

INFLUENCE OF RACE ON COMPLICATIONS OF INTENSIVE CHEMOTHERAPY IN AML

EHA Library, Ivy Abraham, 386379

EVALUATION OF PROGNOSTIC FACTORS FOR SURVIVAL AND TREATMENT OUTCOMES OF PATIENTS WITH SECONDARY ACUTE MYELOID LEUKEMIA – A SINGLE-CENTER STUDY

EHA Library, Piotr Strzałka, 386380

MEASURABLE RESIDUAL DISEASE DETECTED BY WT1 IS AN INDEPENDENT PREDICTOR OF SURVIVAL IN CHILDREN WITH ACUTE MYELOID LEUKEMIA

EHA Library, Mariam Elsherif, 386381

PRELIMINARY RESULTS OF MRD ANALYSIS OF AML1718, A PHASE 2 OPEN-LABEL STUDY OF VENETOCLAX, FLUDARABINE, IDARUBICIN AND CYTARABINE (V-FLAI) IN THE INDUCTION THERAPY OF NON LOW-RISK AML

EHA Library, Paola Minetto, 386382

RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)

EHA Library, Katja Sockel, 386383

OLUTASIDENIB IN POST-VENETOCLAX PATIENTS WITH MUTANT IDH1 AML

EHA Library, Jorge Cortes, 386384

A NEW MULTIPLEX PCR TOOL ENABLES TIMELY IDENTIFICATION OF ACTIONABLE TARGETS FOR MOLECULAR-GUIDED THERAPY IN PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Friedrich Stölzel, 386385

LIFETIME CLINICAL OUTCOMES OF CPX-351 VERSUS 7+3 MODELED FROM THE 5-YEAR RESULTS OF A RANDOMIZED PHASE 3 TRIAL FOR OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKAEMIA

EHA Library, Lin Fan, 386386

ABSOLUTE LYMPHOCYTE COUNT IS AN INDEPENDENT SURVIVAL PREDICTOR COMPARED TO MINIMAL RESIDUAL DISEASE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH INTENSIVE CHEMOTHERAPY

EHA Library, Gianluca Cristiano, 386387

IMPROVEMENT IN OVERALL AND RELAPSE FREE SURVIVAL OF AML PATIENTS OVER THE AGE OF 75 SINCE THE APPROVAL OF VENETOCLAX IN A REAL-WORLD SINGLE CENTER STUDY.

EHA Library, Yakir Moshe, 386389

REVUMENIB IN PATIENTS WITH ACUTE LEUKEMIAS: COMPASSIONATE USE PROGRAM EXPERIENCE

EHA Library, C. Michel Zwaan, 386390

CAPILLARY BLOOD SAMPLING ALLOWS FEASIBLE METHOD FOR VENETOCLAX CONCENTRATION MEASUREMENT IN AN ACADEMIC MULTICENTER CLINICAL TRIAL CONTEXT

EHA Library, Sari Kytölä, 386391

NOVEL GENES EXHIBITING FUNCTIONAL RELEVANCE IN KOREAN PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

EHA Library, Jiyeon Kim, 386392

HOMOHARRINGTONINE AND CYTARABINE COMBINED WITH VENETOCLAX (HAV) FOR ADULT PATIENTS WITH DE NOVO AML

EHA Library, Xiao-Hua Luo, 386393

REAL-WORLD DATA AS SUPPLEMENTARY CONTROLS FOR THE PROSPECTIVE RANDOMIZED HOVON-103 TRIAL IN INTENSIVELY TREATED ELDERLY ACUTE MYELOID LEUKEMIA PATIENTS

EHA Library, Sjoerd Hermans, 386394

RESULTS OF NON-CHEMOTERAPEUTIC TREATMENT OF PATIENTS WITH DE NOVO ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Vera Troitskaya, 386395

COMPARISON OF VENETOCLAX-BASED INDUCTION THERAPY OR 3+7 FOLLOWED BY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR NEWLY DIAGNOSED AML PATIENTS

EHA Library, Tran-Der Tan, 386397

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IMPROVES OVERALL AND RELAPSE-FREE SURVIVAL IN PREGNANT WOMEN WITH ACUTE MYELOID LEUKEMIA

EHA Library, Vera Troitskaya, 386398

VENETOCLAX PLUS HYPOMETHYLATING AGENTS VERSUS INTENSIVE CHEMOTHERAPY FOR HEMATOLOGICAL RELAPSE OF MYELOID MALIGNANCIES AFTER ALLO-HSCT

EHA Library, Zhangjie Chen, 386399

OUTPATIENT INITIATION OF VENETOCLAX-AZACITIDINE FOR SELECTED ACUTE MYELOID LEUKEMIA PATIENTS IS FEASIBLE AND SAFE: A REAL WORLD SINGLE CENTER ANALYSIS

EHA Library, Roi Gat, 386400

REAL-WORLD MANAGEMENT AND OUTCOMES FOR NEWLY DIAGNOSED AML PATIENTS INITIATING VENETOCLAX AND HYPOMETHYLATING AGENTS IN US COMMUNITY PRACTICE

EHA Library, Yuexi Wang, 386401

NOVEL PROGNOSTIC MODEL FOR RELAPSE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA RECEIVING HAPLOIDENTICAL HEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Qi Wen, 386402

DIAGNOSIS AND TREATMENT OF T/MYELOID MIXED PHENOTYPE ACUTE LEUKAEMIA (T/M-MPAL)- A UK SINGLE CENTRE EXPERIENCE

EHA Library, Enas Abusalim, 386403

GILTERITINIB MAINTENANCE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION FOR FLT3 MUTATED ACUTE MYELOID LEUKEMIA

EHA Library, Andrius Žučenka, 386404

PREVALENCE AND CLINICAL SIGNIFICANCE OF GERMLINE MUTATIONS IN ACUTE MYELOID LEUKEMIA PATIENTS - A SINGLE-CENTER EXPERIENCE

EHA Library, Chrishthuka Kangatharan, 386405

EFFICACY OF SELINEXOR COMBINED WITH A HYPOMETHYLATING AGENT IN THE TREATMENT OF REFRACTORY/RELAPSED ACUTE MYELOID LEUKEMIA IN PATIENTS EXPOSED TO VENETOCLAX

EHA Library, Jian Zhang, 386406

EFFECTIVENESS OF REINDUCTION CHEMOTHERAPY USING BORTEZOMIB WITH HOMOHARRINGTONINE AND CYTARABINE IN REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA: A PHASE II, MULTICENTER, PROSPECTIVE CLINICAL TRIAL

EHA Library, chengtao zhang, 386407

SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ANTITUMOR ACTIVITY OF AZD5991 IN RELAPSED/ REFRACTORY HEMATOLOGIC MALIGNANCIES: A PHASE 1 FIRST-IN-HUMAN STUDY

EHA Library, Pinkal Desai, 386408

CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH WT1 MUTATED MYELOID NEOPLASMS: MAYO CLINIC EXPERIENCE

EHA Library, Rami Basmaci, 386409

A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA

EHA Library, Mithunan Ravindran, 386410

AZACITIDINE COMBINED WITH HAG REGIMEN AS INDUCTION THERAPY IN ADULT AML PATIENTS

EHA Library, Hong Pan, 386411

PROGNOSTIC IMPLICATIONS OF WT1 MUTATIONS IN PATIENTS WITH DE NOVO AND RELAPSED ACUTE MYELOID LEUKEMIA IN THE ERA OF NOVEL TARGETED THERAPIES

EHA Library, Himachandana Atluri, 386412

VENETOCLAX PLUS HOMOHARRINGTONINE-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH ACUTE MYELOID LEUKAEMIA: A MULTICENTRE, SINGLE-ARM, PHASE 2 TRIAL

EHA Library, Huafeng Wang, 386413

IMPACT OF MYELOID MUTATION PROFILE ON PCR RESPONSES AND SURVIVAL IN PATIENTS WITH CORE-BINDING FACTOR AML TREATED WITH FLAG BASED REGIMES

EHA Library, Jayastu Senapati, 386414

POTENTIAL DRUG-DRUG INTERACTIONS OF ANTIFUNGAL PROPHYLAXIS AND MIDOSTAURIN IN FLT3-MUTATED ACUTE MYELOID LEUKEMIA – CLINICAL IMPLICATIONS OF THERAPEUTIC DRUG MONITORING

EHA Library, Carolin Joisten, 386415

REAL-WORLD CHARACTERISTICS AND USE OF ANTIEMETIC THERAPIES AMONG PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED WITH ORAL AZACITIDINE MAINTENANCE THERAPY

EHA Library, Ying Qiu, 386416

A MULTIPARAMETER FLOW CYTOMETRY PANEL FOR SIMPLE AND RAPID DIAGNOSIS OR SCREENING OF MALIGNANT TUMORS AND RELATED DISEASES

EHA Library, Hui Wang, 386417

MODIFICATIONS IN PRIMARY HEMOSTASIS AS ADDITIONAL RISK FACTORS OF BLEEDING IN PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): UKRAINIAN PROSPECTIVE STUDY IN A REAL-LIFE COHORT.

EHA Library, Zinaida Stupakova, 386419

EXPRESSION PATTERNS AND CLINICAL RELEVANCE OF IMMUNE CHECKPOINT RECEPTORS AND LIGANDS IN ACUTE MYELOID LEUKEMIA

EHA Library, Milan Jagurinoski, 386420

SINGLE-CELL RNA SEQUENCING REVEALS THE SPATIAL HETEROGENEITY OF EXHAUSTED T CELLS IN BTKI-RESISTANT RICHTER TRANSFORMATION PATIENTS

EHA Library, Yeqin Sha, 386421

T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Eric Eldering, 386422

THE CXCR4-LOW/CD5-HIGH PROLIFERATIVE FRACTION IS ENRICHED IN BTK MUTATIONS AND ANTICIPATES RELAPSE IN IBRUTINIB-TREATED CLL

EHA Library, Federico Pozzo, 386423

DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

EHA Library, Helga Simon-Molas, 386424

DELETION OF THE SHORT ARM OF CHROMOSOME 8 AND TNFRSF10B LOSS ASSOCIATE TO POOR PROGNOSIS AND DRUG RESISTANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Ludovic Jondreville, 386425

XPO1 MUTATIONS IDENTIFY EARLY STAGE CLL CHARACTERIZED BY SHORTER TIME TO FIRST TREATMENT AND ENHANCED BCR SIGNALING

EHA Library, Donatella Talotta, 386426

DISRUPTION IN ONE-CARBON METABOLISM THROUGH MTHFD1 INHIBITION AS NOVEL THERAPEUTIC STRATEGY IN CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Elodie Viry, 386427

ACALABRUTINIB IMPROVES INNATE IMMUNE FUNCTION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Rebecca Teglgaard, 386428

DNA METHYLATION ANALYSIS OF B-CELL PROLYMPHOCYTIC LEUKEMIA REVEALS TWO EPIGENETIC SUBTYPES WITH DISTINCT BIOLOGICAL AND CLINICAL FEATURES

EHA Library, Stella Charalampopoulou, 386429

GENETIC DRIVERS IN THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA DEVELOPMENT AS EARLY AS 16 YEARS BEFORE DIAGNOSIS

EHA Library, Pieter Martijn Kolijn, 386430

SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.

EHA Library, Terézia Kurucová, 386431

INFECTIONS BEFORE AND DURING IMMUNOGLOBULIN REPLACEMENT THERAPY IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA.

EHA Library, Christian Brieghel, 386432

CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE SENSITIVE TO THE APOLIPOPROTEIN E-MEDIATED DISRUPTION OF METABOLIC HOMEOSTASIS

EHA Library, Federica Nardi, 386433

IMMUNOGENETICS AND ANTIGEN REACTIVITY PROFILING CONTRIBUTE TO UNRAVELLING THE ONTOGENY OF CLL STEREOTYPED SUBSET #4

EHA Library, Anastasia Iatrou, 386434

MEASUREMENT OF INTRACLONAL DIVERSIFICATION REFINES THE PROGNOSTIC IMPACT OF IGHV MUTATIONS IN CLL

EHA Library, Filippo Vit, 386435

INTEGRATING MULTI-OMICS TO REVEAL THE CLONAL EVOLUTIONARY CHARACTERISTICS IN CLL PATIENTS WITH ZANUBRUTINIB RESISTANCE

EHA Library, Huayuan Zhu, 386436

THE EXPRESSION OF CYTOR LNCRNA HAS POOR PROGNOSTIC VALUE IN CLL PATIENTS AND IS ASSOCIATED WITH MICROENVIRONMENTAL STIMULI.

EHA Library, Lluís Hernández, 386437

EFFECT OF LONG-TERM ZANUBRUTINIB TREATMENT ON T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A STUDY CONDUCTED IN PARALLEL WITH THE BGB-3111-304 AND 305 TRIALS.

EHA Library, Maria Andersson, 386438

EXTRACELLULAR VESICLES FROM CHRONIC LYMPHOCYTIC LEUKEMIA CELLS INDUCE THE DIFFERENTIATION OF MONOCYTES INTO NURSE-LIKE CELLS

EHA Library, Nathan DUBOIS, 386439

CD37 AS A MOLECULAR TARGET FOR CAR-T CELLS AGAINST CHRONIC LYMPHOCYTIC LEUKEMIA

EHA Library, Aleksandra Kusowska, 386440

ASSESSMENT OF THE DEVELOPMENT OF B CELL MALIGNANCIES IN A NOVEL MURINE MODEL CARRYING DLEU2 DELETION

EHA Library, Alice Ramassone, 386441

ANALYSIS OF EX-VIVO RESPONSE TO SINGLE DRUGS AND DRUG COMBINATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENT SAMPLES

EHA Library, Leonardo Miranda Santana, 386442

NOVEL SPLICE-SITE MUTATION IN PLCG2 ASSOCIATED WITH RESISTANCE TO BTK INHIBITORS

EHA Library, Jialei Qi, 386443

GENE-GENE INTERACTIONS IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH VARIOUS CYTOGENETIC PROGNOSTIC FACTORS

EHA Library, Elena Nazarova, 386444

LONG-TERM FOLLOW-UP UPDATE AND MULTIVARIABLE ANALYSES OF FACTORS ASSOCIATED WITH DURATION OF RESPONSE AFTER CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY CLL

EHA Library, Emily Liang, 386445

TRACKING  DISEASE PARAMETERS BY MRD, CT AND PET IN FIRST LINE CLL PATIENTS TREATED WITH FIXED DURATION IBRUTINIB-VENETOCLAX; INTERIM ANALYSIS OF THE FIRST 30 PATIENTS IN HOVON 158/NEXT STEP TRIAL.

EHA Library, Sabina Kersting, 386448

GENETIC ALTERATIONS AND OUTCOMES WITH FIXED-DURATION IBRUTINIB+VENETOCLAX (IBR+VEN): RESULTS FROM THE PHASE 3 GLOW STUDY IN PATIENTS WITH PREVIOUSLY UNTREATED CLL

EHA Library, Arnon P. Kater, 386449

REAL-WORLD DOSING PATTERNS AND TIME TO NEXT TREATMENT FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL/SLL WITH OR WITHOUT IBRUTINIB DOSE REDUCTION FOLLOWING AN ADVERSE EVENT

EHA Library, Mazyar Shadman, 386450

GENETIC MARKERS AND OUTCOME OF CLL PATIENTS IN COMBINED TIME-LIMITED TREATMENT WITH ANTI-CD20 ANTIBODY + IBRUTINIB, IDELALISIB OR VENETOCLAX IN THE GCLLSG CLL2-BAG, -BCG, -BIG AND -BIO PHASE-II TRIALS

EHA Library, Deyan Yosifov, 386451

MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT BTK INHIBITOR

EHA Library, Othman Al-Sawaf, 386452

PHASE 1 STUDY OF JNJ-67856633, A FIRST-IN-HUMAN HIGHLY SELECTIVE MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B-CELL NON-HODGKIN LYMPHOMA (B-NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

EHA Library, Matko Kalac, 386453

A PHASE 1B/2 STUDY OF NAVTEMADLIN COMBINED WITH ACALABRUTINIB IN BTK INHIBITOR NAÏVE PATIENTS WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) OR SMALL LYMPHOCYTIC LYMPHOMA (SLL)

EHA Library, John C. Byrd, 386454

CEVIDOPLENIB (SKI-O-703), A NOVEL SYK INHIBITOR, REDUCES ANTIPHOSPHOLIPID ANTIBODY TITERS AND PREVENTS INTRAMYOCARDIAL SMALL ARTERIAL THROMBOSIS IN A MOUSE MODEL OF ANTIPHOSPHOLIPID SYNDROME

EHA Library, Taeyoung Yoon, 388007

RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN ACUTE PROMYELOCYTIC LEUKEMIA

EHA Library, Nikica Sabljic, 388008

SUSTAINED INHIBITION OF PLATELET ACTIVITY AND THROMBOSIS VIA IV AND ORAL ADMINISTRATION OF CS585

EHA Library, Michael Holinstat, 388009